FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3101740872> ?p ?o ?g. }

• W3101740872 endingPage "5689" @default.
• W3101740872 startingPage "5681" @default.
• W3101740872 abstract "Abstract TP53 mutations are associated with poor outcomes in acute myeloid leukemia (AML). The prognostic impact of mutant TP53 (TP53mut) variant allelic frequency (VAF) is not well established, nor is how this information might guide optimal frontline therapy. We retrospectively analyzed 202 patients with newly diagnosed TP53-mutated AML who underwent first-line therapy with either a cytarabine- or hypomethylating agent (HMA)–based regimen. By multivariate analysis, TP53mut VAF &gt;40% was independently associated with a significantly higher cumulative incidence of relapse (P = .003) and worse relapse-free survival (P = .001) and overall survival (OS; P = .003). The impact of TP53mut VAF on clinical outcomes was driven by patients treated with a cytarabine-based regimen (median OS, 4.7 vs 7.3 months for VAF &gt;40% vs ≤40%; P = .006), whereas VAF did not significantly affect OS in patients treated with HMA. The addition of venetoclax to HMA did not significantly affect OS compared with HMA without venetoclax, both in the entire TP53-mutated population and in patients stratified by TP53mut VAF. Among patients with TP53mut VAF ≤40%, OS was superior in those treated with higher-dose cytarabine, whereas OS was similarly poor for patients with TP53mut VAF &gt;40% regardless of therapy. The best long-term outcomes were observed in those with 1 TP53 mutation with VAF ≤40% who received a frontline cytarabine-based regimen (2-year OS, 38% vs 6% for all others; P &lt; .001). In summary, TP53mut VAF provides important prognostic information that may be considered when selecting frontline therapy for patients with newly diagnosed TP53-mutated AML." @default.
• W3101740872 created "2020-11-23" @default.
• W3101740872 creator A5000750846 @default.
• W3101740872 creator A5006858509 @default.
• W3101740872 creator A5010663972 @default.
• W3101740872 creator A5020340537 @default.
• W3101740872 creator A5022647201 @default.
• W3101740872 creator A5028081179 @default.
• W3101740872 creator A5035605515 @default.
• W3101740872 creator A5051949215 @default.
• W3101740872 creator A5052587844 @default.
• W3101740872 creator A5059373442 @default.
• W3101740872 creator A5061026876 @default.
• W3101740872 creator A5069176297 @default.
• W3101740872 creator A5079262854 @default.
• W3101740872 creator A5079433157 @default.
• W3101740872 creator A5084379902 @default.
• W3101740872 creator A5085348528 @default.
• W3101740872 creator A5091492845 @default.
• W3101740872 date "2020-11-19" @default.
• W3101740872 modified "2023-10-15" @default.
• W3101740872 title "Prognostic and therapeutic impacts of mutant <i>TP53</i> variant allelic frequency in newly diagnosed acute myeloid leukemia" @default.
• W3101740872 cites W2015507761 @default.
• W3101740872 cites W2041356430 @default.
• W3101740872 cites W2052886921 @default.
• W3101740872 cites W2053968609 @default.
• W3101740872 cites W2058794589 @default.
• W3101740872 cites W2075877031 @default.
• W3101740872 cites W2142765738 @default.
• W3101740872 cites W2150754539 @default.
• W3101740872 cites W2199445282 @default.
• W3101740872 cites W2343955238 @default.
• W3101740872 cites W2499799649 @default.
• W3101740872 cites W2513269552 @default.
• W3101740872 cites W2549790759 @default.
• W3101740872 cites W2552699553 @default.
• W3101740872 cites W2559537906 @default.
• W3101740872 cites W2738685991 @default.
• W3101740872 cites W2775236618 @default.
• W3101740872 cites W2804029080 @default.
• W3101740872 cites W2804360523 @default.
• W3101740872 cites W2887033855 @default.
• W3101740872 cites W2892949113 @default.
• W3101740872 cites W2897503030 @default.
• W3101740872 cites W2898284215 @default.
• W3101740872 cites W2905325447 @default.
• W3101740872 cites W2989809064 @default.
• W3101740872 cites W2995529700 @default.
• W3101740872 cites W3000515035 @default.
• W3101740872 cites W3005329625 @default.
• W3101740872 cites W3012511654 @default.
• W3101740872 doi "https://doi.org/10.1182/bloodadvances.2020003120" @default.
• W3101740872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7686900" @default.
• W3101740872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33211826" @default.
• W3101740872 hasPublicationYear "2020" @default.
• W3101740872 type Work @default.
• W3101740872 sameAs 3101740872 @default.
• W3101740872 citedByCount "88" @default.
• W3101740872 countsByYear W31017408722020 @default.
• W3101740872 countsByYear W31017408722021 @default.
• W3101740872 countsByYear W31017408722022 @default.
• W3101740872 countsByYear W31017408722023 @default.
• W3101740872 crossrefType "journal-article" @default.
• W3101740872 hasAuthorship W3101740872A5000750846 @default.
• W3101740872 hasAuthorship W3101740872A5006858509 @default.
• W3101740872 hasAuthorship W3101740872A5010663972 @default.
• W3101740872 hasAuthorship W3101740872A5020340537 @default.
• W3101740872 hasAuthorship W3101740872A5022647201 @default.
• W3101740872 hasAuthorship W3101740872A5028081179 @default.
• W3101740872 hasAuthorship W3101740872A5035605515 @default.
• W3101740872 hasAuthorship W3101740872A5051949215 @default.
• W3101740872 hasAuthorship W3101740872A5052587844 @default.
• W3101740872 hasAuthorship W3101740872A5059373442 @default.
• W3101740872 hasAuthorship W3101740872A5061026876 @default.
• W3101740872 hasAuthorship W3101740872A5069176297 @default.
• W3101740872 hasAuthorship W3101740872A5079262854 @default.
• W3101740872 hasAuthorship W3101740872A5079433157 @default.
• W3101740872 hasAuthorship W3101740872A5084379902 @default.
• W3101740872 hasAuthorship W3101740872A5085348528 @default.
• W3101740872 hasAuthorship W3101740872A5091492845 @default.
• W3101740872 hasBestOaLocation W31017408721 @default.
• W3101740872 hasConcept C104317684 @default.
• W3101740872 hasConcept C126322002 @default.
• W3101740872 hasConcept C143998085 @default.
• W3101740872 hasConcept C150194340 @default.
• W3101740872 hasConcept C190727270 @default.
• W3101740872 hasConcept C2776012956 @default.
• W3101740872 hasConcept C2777938653 @default.
• W3101740872 hasConcept C2778041864 @default.
• W3101740872 hasConcept C2778461978 @default.
• W3101740872 hasConcept C2778729363 @default.
• W3101740872 hasConcept C2779282312 @default.
• W3101740872 hasConcept C2779675984 @default.
• W3101740872 hasConcept C2781413609 @default.
• W3101740872 hasConcept C2908647359 @default.
• W3101740872 hasConcept C38180746 @default.
• W3101740872 hasConcept C54355233 @default.
• W3101740872 hasConcept C71924100 @default.

• next